Company intelligence / Profile preview

Beijing Aikang Weijian Pharmaceutical Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Aikang Weijian Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in China, primarily focused on the development of innovative small molecule drugs for metabolic diseases. The company's lead program is AKW607, a potent and selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Aikang Weijian aims to address significant unmet medical needs in the metabolic space by leveraging its internal R&D capabilities to advance candidates through clinical validation. The company is currently progressing its pipeline through various stages of clinical development in the Chinese market.

Therapeutic areas: RheumatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Beijing Aikang Weijian Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Aikang Weijian Pharmaceutical Technology.

Explore the full profile